S Bank Fund Management Ltd Buys Shares of 43,508 Royalty Pharma PLC $RPRX

Key Points

• S Bank Fund Management Ltd acquired 43,508 shares of Royalty Pharma PLC valued at approximately $1,568,000 during the 2nd quarter.
• Royalty Pharma recently reported an earnings per share (EPS) of $1.14, beating the consensus estimate, alongside quarterly revenue of $578.67 million.
• The company declared a quarterly dividend of $0.22 per share, resulting in an annualized dividend yield of 2.4%.

S Bank Fund Management Ltd purchased a new stake in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 43,508 shares of the biopharmaceutical company's stock, valued at approximately $1,568,000.

Several other large investors have also recently added to or reduced their stakes in RPRX. Victory Capital Management Inc. increased its holdings in shares of Royalty Pharma by 270.4% during the first quarter. Victory Capital Management Inc. now owns 3,623,134 shares of the biopharmaceutical company's stock valued at $112,788,000 after purchasing an additional 2,644,923 shares during the period. Los Angeles Capital Management LLC increased its stake in Royalty Pharma by 2,543.7% in the 1st quarter. Los Angeles Capital Management LLC now owns 1,081,128 shares of the biopharmaceutical company's stock worth $33,656,000 after purchasing an additional 1,040,234 shares in the last quarter. Jupiter Asset Management Ltd. boosted its position in Royalty Pharma by 462.1% during the 1st quarter. Jupiter Asset Management Ltd. now owns 1,090,591 shares of the biopharmaceutical company's stock worth $33,950,000 after acquiring an additional 896,555 shares during the period. Nuveen LLC acquired a new stake in Royalty Pharma during the 1st quarter worth about $27,749,000. Finally, AQR Capital Management LLC boosted its position in Royalty Pharma by 37.0% during the 1st quarter. AQR Capital Management LLC now owns 2,608,090 shares of the biopharmaceutical company's stock worth $80,381,000 after acquiring an additional 704,414 shares during the period. 54.35% of the stock is owned by institutional investors and hedge funds.

Royalty Pharma Stock Up 0.5%

RPRX stock opened at $36.18 on Thursday. The company has a quick ratio of 1.26, a current ratio of 1.26 and a debt-to-equity ratio of 0.74. The business has a 50 day moving average price of $36.08 and a two-hundred day moving average price of $34.72. The company has a market cap of $21.10 billion, a price-to-earnings ratio of 20.91, a P/E/G ratio of 1.98 and a beta of 0.60. Royalty Pharma PLC has a twelve month low of $24.05 and a twelve month high of $38.00.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its earnings results on Wednesday, August 6th. The biopharmaceutical company reported $1.14 EPS for the quarter, topping the consensus estimate of $1.10 by $0.04. The company had revenue of $578.67 million during the quarter, compared to the consensus estimate of $750.06 million. Royalty Pharma had a return on equity of 25.54% and a net margin of 44.23%. Analysts anticipate that Royalty Pharma PLC will post 4.49 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th were issued a dividend of $0.22 per share. The ex-dividend date of this dividend was Friday, August 15th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.4%. Royalty Pharma's payout ratio is 50.87%.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Citigroup raised their price objective on Royalty Pharma from $40.00 to $42.00 and gave the company a "buy" rating in a research note on Tuesday, July 22nd. Weiss Ratings upgraded Royalty Pharma from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday, October 8th. Wall Street Zen lowered Royalty Pharma from a "buy" rating to a "hold" rating in a research note on Saturday, September 13th. The Goldman Sachs Group initiated coverage on Royalty Pharma in a research report on Tuesday, September 30th. They issued a "buy" rating and a $42.00 price target on the stock. Finally, Morgan Stanley reduced their price objective on Royalty Pharma from $55.00 to $54.00 and set an "overweight" rating on the stock in a research note on Friday, October 10th. One equities research analyst has rated the stock with a Strong Buy rating and four have given a Buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $46.00.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

Want to see what other hedge funds are holding RPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Royalty Pharma PLC (NASDAQ:RPRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.